-
Achilles Therapeutics NASDAQ:ACHL Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Location: London, W6 8PW, United Kingdom | Website: www.achillestx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-48.48M
Cash
95.11M
Avg Qtr Burn
-12.0M
Short % of Float
0.02%
Insider Ownership
6.52%
Institutional Own.
62.47%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATL001 (TIL cNeT) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Failed Discontinued | |
ATL001 (cNeT) +/- Nivolumab (anti-PD-1) Details Melanoma, Cancer, Solid tumor/s | Failed Discontinued |